TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39431577

Group type: EXPERIMENTAL
Intervention: Sweden and Norway
Number of subjects: 45151

Group type: COMPARATOR
Intervention: 12 WHO European countries
Number of subjects: 45151
Study: 39431909

Group type: EXPERIMENTAL
Intervention: Multimodal treatment for ADHD, details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available.
Number of subjects: 0
Study: 39432135

Group type: EXPERIMENTAL
Intervention: Gensini score
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Combined four OCT criteria
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Thin fibrous cap
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Lipid arc > 180°
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Minimum lumen area < 3.5 mm
Number of subjects: 847
Study: 39432158

Group type: EXPERIMENTAL
Intervention: SH-trehalose
Number of subjects: 312
Study: 39432161

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg PO daily
Number of subjects: 113
Study: 39432177

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) treatment
Number of subjects: 475

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 475
Study: 39432189

Group type: EXPERIMENTAL
Intervention: Breast cancer digital tool (in addition to standard care)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 166
Study: 39432253

Group type: EXPERIMENTAL
Intervention: CT-μFR
Number of subjects: 260
Study: 39432255

Group type: EXPERIMENTAL
Intervention: Revascularisation (REV)
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 1236
Study: 39432252

Group type: EXPERIMENTAL
Intervention: Intravenous cangrelor
Number of subjects: 550

Group type: COMPARATOR
Intervention: Crushed ticagrelor (180 mg loading dose)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 550
Study: 39432286

Group type: EXPERIMENTAL
Intervention: Mailing of educational materials to both the patient and their prescribing clinician
Number of subjects: 12787

Group type: EXPERIMENTAL
Intervention: Mailing to the prescribing clinician only
Number of subjects: 12787

Group type: COMPARATOR
Intervention: Usual care arm
Number of subjects: 12787
Study: 39432292

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention connecting primary care, home, and school settings.
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Primary care and school interventions (various programs including Yes We Can Children's Asthma Program, Open Airways For Schools Plus, and school-based asthma therapy).
Number of subjects: 626
Study: 39432296

Group type: EXPERIMENTAL
Intervention: 3 cycles of CEV chemotherapy
Number of subjects: 187

Group type: COMPARATOR
Intervention: 6 cycles of CEV chemotherapy
Number of subjects: 187
Study: 39432308

Group type: EXPERIMENTAL
Intervention: Communities That HEAL (CTH) intervention
Number of subjects: 8211506

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8211506
Study: 39432369

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39432457

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4,000 IU capsule daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 39432509

Group type: EXPERIMENTAL
Intervention: Bedaquiline 800 mg with rifampicin 600 mg (BE-PEP)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Rifampicin 600 mg alone (SDR-PEP)
Number of subjects: 313
Study: 39432734

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 39432738

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50 mg daily
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 200/50 mg
Number of subjects: 191
Study: 39432745

Group type: EXPERIMENTAL
Intervention: CBG-002 therapy
Number of subjects: 11
Study: 39432808

Group type: EXPERIMENTAL
Intervention: Chronic pelvic pain patients
Number of subjects: 564

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 564
Study: 39432867

Group type: EXPERIMENTAL
Intervention: DKN-01 300 mg once every 2 weeks, tislelizumab 200 mg once every 3 weeks, oxaliplatin 130 mg/m2
Number of subjects: 25
Study: 39432892

Group type: EXPERIMENTAL
Intervention: Self-guided digital family skills management program
Number of subjects: 37
Study: 39432898

Group type: EXPERIMENTAL
Intervention: GDM-Dhulikhel Hospital (GDM-DH) app plus standard care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 120
Study: 39432928

Group type: EXPERIMENTAL
Intervention: Excessive GWG in T1
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Excessive GWG in T2
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Overall sample across GWG categories
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Excessive GWG in T1 and T2
Number of subjects: 221
Study: 39433132

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) treatment for 8 weeks
Number of subjects: 909
Study: 39433199

Group type: EXPERIMENTAL
Intervention: Unilateral ovariectomy for ovarian tissue cryopreservation (OTC)
Number of subjects: 28
Study: 39433413

Group type: EXPERIMENTAL
Intervention: MI with neurofeedback
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: MI alone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (watching movies and visualisation of geometric shapes)
Number of subjects: 21
Study: 39433597

Group type: EXPERIMENTAL
Intervention: Click detector using a chronically implanted high density electrocorticographic (ECoG) BCI with coverage of the sensorimotor cortex.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: New click detector trained with less than 15 minutes of data within 1 day.
Number of subjects: 1
Study: 39433921

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Sham tDCS (0 mA)
Number of subjects: 174
Study: 39433968

Group type: EXPERIMENTAL
Intervention: Renal fractional flow reserve (rFFR)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Color Doppler ultrasonography (CDU) parameters
Number of subjects: 58
Study: 39434066

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) for 8 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Baseline period (no intervention)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE)
Number of subjects: 150
Study: 39434072

Group type: EXPERIMENTAL
Intervention: Virtual facilitation workshop
Number of subjects: 30
Study: 39434107

Group type: EXPERIMENTAL
Intervention: Exercise and Lifestyle Education Program (ExLE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise Program (Ex)
Number of subjects: 0
Study: 39434114

Group type: EXPERIMENTAL
Intervention: Fisetin (single oral dose of 20 mg/kg)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Fisetin (two oral doses of 20 mg/kg each spaced 1 day apart)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 39434121

Group type: EXPERIMENTAL
Intervention: Digital remote postoperative monitoring
Number of subjects: 28
Study: 39434160

Group type: EXPERIMENTAL
Intervention: Resistance and endurance circuit training program (exercise group, n=34)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (16:8) combined with training program (combination group, n=28)
Number of subjects: 62
Study: 39434171

Group type: EXPERIMENTAL
Intervention: Robotic-assisted total mesorectal excision (RATME)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic-assisted total mesorectal excision (LATME)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RATME
Number of subjects: 0

Group type: COMPARATOR
Intervention: LATME
Number of subjects: 0
Study: 39434179

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation programme (ten 1-hour sessions, delivered weekly)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard clinical care without cognitive rehabilitation
Number of subjects: 120
Study: 39434191

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (LR) for fluid resuscitation for at least 48 hours
Number of subjects: 720

Group type: COMPARATOR
Intervention: Normal saline (NS) for fluid resuscitation for at least 48 hours
Number of subjects: 720
Study: 39434193

Group type: EXPERIMENTAL
Intervention: Single-session mindfulness-based intervention (90-minute group-based session with mindfulness practices and psychoeducation, followed by app-based follow-up)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education session on dementia care (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-session mindfulness-based intervention
Number of subjects: 0
Study: 39434431

Group type: EXPERIMENTAL
Intervention: Cofrogliptin 10 mg
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Cofrogliptin 25 mg
Number of subjects: 475

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study: 39434549

Group type: EXPERIMENTAL
Intervention: Prevention strategy using the Risk of Recurrence Ulcer Tool
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early detection strategy using the Risk of Recurrence Ulcer Tool
Number of subjects: 0
Study: 39434554

Group type: EXPERIMENTAL
Intervention: Polymer free biolimus coated coronary stent (PF-BCS)
Number of subjects: 914
Study: 39434634

Group type: EXPERIMENTAL
Intervention: Tegoprazan-containing sequential therapy
Number of subjects: 406

Group type: COMPARATOR
Intervention: Esomeprazole-containing sequential therapy
Number of subjects: 406
Study: 39434728

Group type: EXPERIMENTAL
Intervention: 0.05% chlorhexidine gluconate (CHG) irrigation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional antibiotic irrigation (rifampin 600 mg/L of sterile water, gentamicin 80 mg/L of sterile water)
Number of subjects: 100
Study: 39435126

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (NS) plus SSRI/SNRI
Number of subjects: 696

Group type: COMPARATOR
Intervention: Real-world treatment (RWT)
Number of subjects: 696
Study: 39435124

Group type: EXPERIMENTAL
Intervention: Feel-Good inpatient therapy group
Number of subjects: 10
Study: 39435268

Group type: EXPERIMENTAL
Intervention: Tislelizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 0
Study: 39435321

Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 6905

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6905

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination
Number of subjects: 6905
Study: 39435387

Group type: EXPERIMENTAL
Intervention: AquOTic intervention (10-week occupational therapy-based aquatic intervention)
Number of subjects: 37
Study: 39435392

Group type: EXPERIMENTAL
Intervention: Single-use rhinolaryngoscopes (SURLs)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Reusable rhinolaryngoscopes (RRLs)
Number of subjects: 26
Study: 39435603

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell-derived exosome-based therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparative analysis of therapies utilizing mesenchymal stem cells and exosomes
Number of subjects: 0
Study: 39435713

Group type: EXPERIMENTAL
Intervention: Intravenous tenecteplase plus endovascular thrombectomy
Number of subjects: 544

Group type: COMPARATOR
Intervention: Endovascular thrombectomy alone
Number of subjects: 544
Study: 39435908

Group type: EXPERIMENTAL
Intervention: 1.0 or 2.5 mg parsaclisib orally once daily for 12 weeks
Number of subjects: 25
Study: 39436237

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Healthy Diet Indicator (HDI)
Number of subjects: 165
Study: 39436270

Group type: EXPERIMENTAL
Intervention: Graded motor imagery plus multimodal physical therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Multimodal physical therapy alone
Number of subjects: 38
Study: 39436295

Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 0
Study: 39436396

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) waitlist
Number of subjects: 64
Study: 39436413

Group type: EXPERIMENTAL
Intervention: Prefilled pen device
Number of subjects: 150

Group type: COMPARATOR
Intervention: Prefilled syringe
Number of subjects: 150
Study: 39436476

Group type: EXPERIMENTAL
Intervention: Elevated Systemic Immune-Inflammation Index (SII) > 0.437
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elevated Systemic Immune-Inflammation Index (SII) > 0.437 in patients ≥ 65 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elevated Systemic Immune-Inflammation Index (SII) > 0.437 in patients on clopidogrel plus aspirin therapy
Number of subjects: 0
Study: 39436553

Group type: EXPERIMENTAL
Intervention: Turkish version of North Star Ambulatory Assessment (T-NSAA)
Number of subjects: 86
Study: 39436590

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cryoablation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine surgical practice (control group)
Number of subjects: 20
Study: 39436588

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Bisoprolol + Ramipril
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Mean Heart Dose (MHD) for patients with no subclinical damage
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Mean Heart Dose (MHD) for patients with subclinical heart damage
Number of subjects: 39
Study: 39436613

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccination (boosted)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Unvaccinated and not up-to-date with COVID-19 vaccination
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Cluster 3 (high symptoms, >6 symptoms)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Cluster 1 (low symptoms, <2 symptoms) and Cluster 2 (moderate symptoms, 2-6 symptoms)
Number of subjects: 328
Study: 39436684

Group type: EXPERIMENTAL
Intervention: FACET home monitoring system along with standard treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 90
Study: 39436695

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes (T1D)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 30
Study: 39436905

Group type: EXPERIMENTAL
Intervention: Investigational hand therapy intervention
Number of subjects: 49

Group type: COMPARATOR
Intervention: Traditional occupational therapy approach
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study: 39436955

Group type: EXPERIMENTAL
Intervention: Triple therapy for COPD
Number of subjects: 1213

Group type: COMPARATOR
Intervention: Dual bronchodilation (LAMA + LABA)
Number of subjects: 1213
Study: 39437010

Group type: EXPERIMENTAL
Intervention: BAY 2666605
Number of subjects: 5
Study: 39437136

Group type: EXPERIMENTAL
Intervention: LSM by 2D-SWE
Number of subjects: 2340

Group type: EXPERIMENTAL
Intervention: Algorithm (PLEASE)
Number of subjects: 2340
Study: 39437217

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg 3× per day for 20 days before and 10 days after surgery)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Metformin and Placebo
Number of subjects: 48
Study: 39437312

Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg once daily
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 39437435

Group type: COMPARATOR
Intervention: Control (24 h high-carbohydrate diet followed by the incremental test)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glycogen depletion (glycogen-depletion protocol followed by 24 h low-carbohydrate diet and then the incremental test)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Heat (24 h high-carbohydrate diet followed by 30 min passive heating and then the incremental test in heat)
Number of subjects: 20
Study: 39437546

Group type: EXPERIMENTAL
Intervention: Venetoclax (Ven) 400 mg daily with biweekly Pegcrisantaspase (PegC) 750 IU/m2
Number of subjects: 25
Study: 39437708

Group type: EXPERIMENTAL
Intervention: zanubrutinib 160mg twice daily and obinutuzumab 1000mg on cycle 1 day 1, 8, 15 and day 1 of cycles 2-8, followed by venetoclax with weekly dose-ramp up to 400mg daily after 2 cycles
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: zanubrutinib, obinutuzumab, and venetoclax (BOVen)
Number of subjects: 25
Study: 39437815

Group type: EXPERIMENTAL
Intervention: Gas chromatography-ion mobility spectrometry (GC-IMS) analysis of volatile organic compounds (VOCs) in exhaled breath, blood, and urine.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Gas chromatography-ion mobility spectrometry (GC-IMS) analysis of VOCs in breath, urine, and blood.
Number of subjects: 70
Study: 39438001

Group type: EXPERIMENTAL
Intervention: nal-IRI plus 5-FU/LV
Number of subjects: 277

Group type: COMPARATOR
Intervention: mFOLFOX
Number of subjects: 277

Group type: COMPARATOR
Intervention: mFOLFIRI
Number of subjects: 277
Study: 39438096

Group type: EXPERIMENTAL
Intervention: DMX-200 120 mg two times per day on background of titratable candesartan commencing at 4 mg two times per day for 28 days.
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo on background of titratable candesartan commencing at 4 mg two times per day for 28 days.
Number of subjects: 49
Study: 39438099

Group type: EXPERIMENTAL
Intervention: END-IT NH 6-component intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study: 39438108

Group type: EXPERIMENTAL
Intervention: Resuming DOAC at standard dosing starting at 30 days (30+7)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resuming DOAC at standard dosing starting at 90 days (90±14)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 39438105

Group type: EXPERIMENTAL
Intervention: Supervised group-based walking intervention
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Unsupervised group-based walking intervention
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Unsupervised individual-based walking intervention
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184
Study: 39438104

Group type: EXPERIMENTAL
Intervention: VR-guided mindfulness intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham VR control (relaxing nature videos)
Number of subjects: 30
Study: 39438126

Group type: EXPERIMENTAL
Intervention: Bisacodyl 10 mg daily for 10 days
Number of subjects: 124

Group type: COMPARATOR
Intervention: Hyoscine 20 mg three times per day for 10 days
Number of subjects: 124
Study: 39438203

Group type: EXPERIMENTAL
Intervention: Untreated severe obstructive sleep apnea (OSA) (AHI≥30 events/h)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Non-OSA (AHI<15 events/h)
Number of subjects: 58
Study: 39438214

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 27
Study: 39438236

Group type: EXPERIMENTAL
Intervention: Peer Enhanced Depression Care
Number of subjects: 149

Group type: COMPARATOR
Intervention: Nonpeer, social interaction control
Number of subjects: 149
Study: 39438322

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 117
Study: 39438442

Group type: EXPERIMENTAL
Intervention: anti-PD-1 (aPD1) plus chemoradiotherapy (CRT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: aPD1-CRT
Number of subjects: 24
Study: 39438467

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (5 mg/day) combined with methylprednisolone (1 mg/kg/day)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Methylprednisolone alone (2 mg/kg/day)
Number of subjects: 198
Study: 39438591

Group type: EXPERIMENTAL
Intervention: Xacrel
Number of subjects: 170

Group type: COMPARATOR
Intervention: Ocrevus
Number of subjects: 170
Study: 39438621

Group type: EXPERIMENTAL
Intervention: Random Forest (RF) ML model in internal validation cohort
Number of subjects: 10874

Group type: EXPERIMENTAL
Intervention: Random Forest (RF) ML model in temporal validation cohort
Number of subjects: 10874
Study: 39438797

Group type: EXPERIMENTAL
Intervention: Barriers and facilitators to social connection identified through thematic analysis.
Number of subjects: 67
Study: 39438885

Group type: EXPERIMENTAL
Intervention: In-person peer support groups
Number of subjects: 500

Group type: COMPARATOR
Intervention: WhatsApp-facilitated mobile groups
Number of subjects: 500
Study: 39438915

Group type: EXPERIMENTAL
Intervention: Adapt 2 Asthma (A2A)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Asthma self-management control arm (APK)
Number of subjects: 280
Study: 39438920

Group type: EXPERIMENTAL
Intervention: Strong Hearts, Healthy Communities 2.0 (SHHC-2.0) intervention
Number of subjects: 11

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 11
Study: 39438942

Group type: EXPERIMENTAL
Intervention: Ertugliflozin (5 mg once daily)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 39439007

Group type: EXPERIMENTAL
Intervention: 7 ml/kg Ringer's Lactate infusion over 10 min
Number of subjects: 40
Study: 39439041

Group type: EXPERIMENTAL
Intervention: Hybrid telemental health (TMH) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hybrid TMH treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-person treatment
Number of subjects: 0
Study: 39439294

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 13194

Group type: COMPARATOR
Intervention: Enalapril or valsartan
Number of subjects: 13194
Study: 39439530

Group type: EXPERIMENTAL
Intervention: Rivaroxaban plus aspirin
Number of subjects: 9049

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 9049
Study: 39439726

Group type: EXPERIMENTAL
Intervention: Personalized mobile chat messaging support for relapse prevention, including cessation advice from a live counselor and access to a supportive chatbot via WhatsApp for 3 months
Number of subjects: 586

Group type: COMPARATOR
Intervention: Text messaging on generic cessation advice for 3 months as attention control
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Personalized mobile chat messaging support for relapse prevention
Number of subjects: 586